

RESEARCH

Open Access



Prevalence of lifestyle cardiovascular risk factors and estimated framingham 10-year risk scores of adults with psychotic disorders compared to controls at a referral hospital in Eldoret, Kenya

Edith Kwobah^{1*}, Nastassja Koen², Ann Mwangi³, Lukoye Atwoli⁴ and Dan J. Stein⁵

Abstract

Introduction Lifestyle factors such as smoking, alcohol use, suboptimal diet, and inadequate physical activity have been associated with increased risk of cardiovascular diseases. There are limited data on these risk factors among patients with psychosis in low- and middle-income countries.

Objectives This study aimed to establish the prevalence of lifestyle cardiovascular risk factors, and the 10-year cardiovascular risk scores and associated factors in patients with psychosis compared to controls at Moi Teaching and Referral Hospital in Eldoret, Kenya.

Methods A sample of 297 patients with schizophrenia, schizoaffective disorder, or bipolar mood disorder; and 300 controls matched for age and sex were included in this analysis. A study specific researcher-administered questionnaire was used to collect data on demographics, antipsychotic medication use, smoking, alcohol intake, diet, and physical activity. Weight, height, abdominal circumference, and blood pressure were also collected to calculate the Framingham 10-year Cardiovascular Risk Score (FRS), while blood was drawn for measurement of glucose level and lipid profile. Pearson's chi-squared tests and t-tests were employed to assess differences in cardiovascular risk profiles between patients and controls, and a linear regression model was used to determine predictors of 10-year cardiovascular risk in patients.

Results Compared to controls, patients with psychosis were more likely to have smoked in their lifetimes (9.9% vs. 3.3%, $p=0.006$) or to be current smokers (13.8% vs. 7%, $p=0.001$). Over 97% of patients with psychosis consumed fewer than five servings of fruits and vegetables per week; 78% engaged in fewer than three days of vigorous exercise per week; and 48% sat for more than three hours daily. The estimated 10-year risk of CVD was relatively low in this study: the FRS in patients was 3.16, compared to 2.93 in controls. The estimated 10-year cardiovascular risk in patients

*Correspondence:

Edith Kwobah
eckamaru@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

was significantly associated with female sex ($p=0.007$), older patients ($p < 0.001$), current tobacco smoking ($p < 0.001$), and metabolic syndrome ($p < 0.001$).

Conclusion In the setting of Eldoret, there is suboptimal physical exercise and intake of healthy diet among patients with psychosis and controls. While the estimated risk score among patients is relatively low in our study, these data may be useful for informing future studies geared towards informing interventions to promote healthy lifestyles in this population.

Keywords Lifestyle, Cardiovascular risk, Psychotic disorders, Eldoret, Kenya, Risk score

Background

Patients with mental illness have an increased mortality rate compared to the general population [1]. Cardiovascular disorders (CVDs), the leading cause of death worldwide [2], contribute significantly to the excess mortality among patients with mental illness, with CVDs accounting for 17.4% and 22.0% of the reduction in life expectancy in males and females, respectively [3]. While early detection and management of these patients have potential to improve outcomes, sadly people with mental disorders receive less screening and lower-quality treatment for CVD. Modifiable CVD risk factors include smoking, alcohol intake, physical inactivity and unhealthy diet [4].

Smoking is one of the leading causes of premature deaths globally and is among the five leading risk factors for ill health, as measured by disability-adjusted life-years (DALYS) [5]. Smoking may lead to accelerated atherogenesis, increased risk of ischemia, arrhythmias and myocardial infarction [6]. The mechanisms underlying increased tobacco use in the mentally ill are likely bidirectional - smoking may increase the risk of psychosis; and patients with psychosis may smoke to alleviate the negative experiences resulting from their symptoms [7].

Harmful alcohol use is the seventh leading cause of death worldwide and a major contributor to DALYS [8]. Excess alcohol intake increases the risk of CVD by contributing to atherosclerosis, increasing rates of hypertension, arrhythmias and dilated cardiomyopathy [9]. The pathways underlying comorbid alcohol use disorder and psychotic disorders are likely multifaceted. For example, patients with schizophrenia may overvalue drug-like reward experiences in addition to experiencing greater euphoria and stimulatory effects in response to alcohol; and may devalue the potential negative consequences of substances. This may be further complicated by detrimental decision-making and impulsive behaviour in this patient group [10].

Inadequate physical activity and sedentary behaviour are both common contributors to many chronic diseases; [11] and are classified as modifiable CVD risk factors [12, 13]. Adequate physical activity is a cost-effective way of promoting cardiovascular health [14]. Meta-analytic evidence indicates that an increase from inactivity

to achieving 2.5 h of moderate-intensity aerobic activity/ week, is associated with lower risk of CVD mortality [15–17].

The benefits of adequate fruit and vegetable intake (i.e. at least half a plate/day) in mitigating CVD risk factors such as DM and obesity, are well documented [18, 19]. Existing literature indicates that about 200 g of fruits and vegetables consumed per day significantly reduces the relative risk for coronary heart disease and for all-cause mortality 0.90 [20]. Studies assessing the dietary patterns of patients with schizophrenia report that these individuals often follow a poor diet (e.g. with increased intake of saturated fats and reduced intake of fruits and vegetables), thus augmenting the risk of metabolic disturbances [21]. Poor dietary habits among patients with psychosis have also been linked to unemployment, negative symptoms of psychosis, economic challenges and low knowledge levels on importance of a healthy diet [22].

To quantify risk and guide intervention, scores have been developed to estimate the 10- year risk of developing CVD. Of these scores, the Framingham risk score (FRS) is the most commonly used in patients with mental illness [23]. FRS is a multivariable risk factor algorithm used to assess general CVD risk and risk of individual CVD events, including coronary, cerebrovascular, and peripheral arterial disease and heart failure [24]. The scores are categorized as low (< 10), intermediate [10–19] and high > 20 . FRS has been reported to be significantly higher among patients with psychosis compared to the general population [25].

While the burden and sequelae of CVDs may be reduced through simple and cost-effective methods such as smoking cessation, improved diet and physical activity, as well as substance use interventions; there is limited evidence from low- and middle-income countries (LMICs) and from Sub-Saharan Africa (SSA) on the prevalence of these risk factors, and on how they relate to overall cardiovascular risk profile. In addition, minimal literature has documented the estimated 10-year cardiovascular risk scores in these settings. This dearth of evidence has likely contributed to limited clinical programs addressing CVD risk factors in patients with psychosis in LMICs and SSA. Thus, this study had two objectives;

1. To determine the prevalence of modifiable lifestyle CVD risk factors among patients treated for psychotic disorders compared to controls at Moi Teaching and Referral Hospital (MTRH) in Eldoret.
2. To document the estimated 10-year risk score and associated factors among patients with psychosis compared to controls in this setting.

Materials and methods

This was an observational study conducted in 2019 at Moi Teaching and Referral Hospital (MTRH), situated in western Kenya, as part of PhD work nested within the larger Neuropsychiatric Genetics of African Populations (NeuroGAP) initiative [26].

For this study, convenience sampling was done. A sample size calculation was carried out as recommended by Peduzzi et al. (1996). These authors recommended that the minimum number of participants to include in a study such as ours should be obtained as follows: $N=10 \times k/p$ where K is the number of covariates and p is the proportion of cases in the population [27]. Using an estimated prevalence of MetS in Kenya of approximately 35% [28] and 10 covariates in the data collection tool: $N=10 \times 10/0.35=285.7$. This sample size is comparable to one prior study by Saloojee et al. which employed a design similar to ours and was conducted in South Africa [29]. To allow for missing data and quality control procedures, we recruited 300 patients and 300 controls frequently matched for age and sex.

Patients were recruited from the booked outpatient consultant clinic at MTRH that takes place every Wednesday of the year. According to the hospital records about 5000 patients are seen in the clinic every year and 60% of these have psychotic disorders. For the purposes of this study, “psychotic disorder” was defined as schizophrenia, schizoaffective and bipolar mood disorders as captured in the *Diagnostic and Statistical Manual, fifth edition* (DSM-5) [30]. On the clinic date participants with a documented diagnosis of bipolar mood disorder, schizoaffective disorder and schizophrenia were identified from the waiting bay using their name and the personal file number. They were given more information on the study and requested to participate.

Adult participants with schizophrenia, schizoaffective disorder, or bipolar mood disorder, with ability to consent were eligible for inclusion. We excluded pregnant women and those who did not have capacity to consent due to cognitive impairment as defined by a score less than 14.5 on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC). Capacity to consent was defined by a score of at least 14.5 and above on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC). UBACC is a 10-item scale with good internal consistency, interrater

reliability and concurrent validity [31]. It also has a short administration time and simple language making it easy to administer. It was translated into Swahili for use in this study setting. The tool was administered in Swahili or English based on the participants preference. Participants with a score less than 14.5 after a maximum of four trials, indicating cognitive inability to consent, were excluded from the study.

Recruitment of control participants took place every day of the week except Wednesday- Wednesday was reserved for patient recruitment given that the clinic only runs once a week. Posters were displayed on the hospital notice boards informing members of the public of the study- students and persons visiting the hospital. Those who expressed interest to participate in the study were asked to contact the research assistant for further information, either telephonically or in person at the hospital. Those who approached the research assistant expressing interest to participate were given more details about the study, and upon accepting to participate written informed consent was taken.

For the control group we included adults aged 18 years and above who consented to participate in the study. We excluded persons known to have an existing mental illness or who were taking any psychiatric medication as determined by self-report or medical record review. We also excluded persons receiving medical treatment for acute alcohol or drug intoxication, as well as pregnant women. Pregnant women were excluded due to the evidence that substantial changes occur in pregnancy including insulin resistance, raised serum glucose as well as changes in lipid metabolism [32].

A researcher-administered questionnaire was used to collect data on demographic variables including age, sex, education level, marital status, current medication use (including antipsychotic medication) and smoking history. The Alcohol use Identification Test (AUDIT – C) was used to screen for harmful alcohol use [33]. The AUDIT-C comprises three questions, each scored on a 5-point Likert scale (minimum score=0; maximum score=4), with the total score ranging from 0 to 12. A score of ≥ 4 in men and ≥ 3 in women has been used previously for identifying an alcohol use disorder [33, 34].

Items assessing diet and exercise were adapted from the WHO Steps Survey, a tool used to measure risk factors for non-communicable diseases [35]. In the current study, we asked patients to reflect about a typical week. We classified adequate exercise as 3–7 days a week of either: (1) vigorous intensity activities that increase one’s breathing and heart rate, as part of one’s work; or (2) walking or riding a bicycle for at least 10 min continuously to get to and from places; or (3) doing vigorous-intensity sports, fitness or recreational (leisure) activities. Fewer than three days of these were classified

as inadequate. Sedentary behaviour was estimated in terms of amount of time spent sitting or reclining as follows: (1) fewer than 3 h in a day (active) or (2) more than 3 h in a day (sedentary). Intake of fruits and vegetables was quantified as number of servings per week. Five or more servings per week was classified as adequate, while fewer than five were classified as inadequate.

In addition to the researcher-administered questionnaires, measurements for weight, height, abdominal circumference, and blood pressure were taken and blood was drawn for blood sugar and a non-fasting lipid profile. These were used to make a diagnosis of metabolic syndrome which according to Adult Treatment Panel III includes Abdominal obesity >102 cm in men, > 88 cm in women, Triglycerides ≥150 mg/dl, High Density Lipoproteins <40 mg/dl or 1mmol/l in men, < 50 mg/dl or 1.3mmol/l in women, Blood pressure ≥130/≥85mmhg or treatment for hypertension, Fasting glucose- ≥ 6.1 mmol/l or treatment for diabetes, Random Blood sugar ≥11.1 mmol/l [36].

Statistical analyses

Statistical analyses were conducted in Stata version 15 for analysis the frequencies of CVD risk factors (i.e.,

smoking, alcohol intake, exercise) Pearson’s chi-squared tests were used to determine differences between patients with psychosis versus controls. FRS was computed using participant age, sex, total cholesterol, High Density Lipoprotein cholesterol, smoking habits, and systolic blood pressure. The scores were then categorized as low (<10), intermediate (10–19) or high (>20). T-tests were used to determine the differences in the means of the Framingham 10-year estimated risk for cardiovascular disorders between the patients and the controls. Logistic regression modelling was then undertaken to explore the predictors of a high FRS in patients with psychosis.

Results

A total of 700 participants were approached, and of these 597 participants (297 cases and 300) controls participants were included in this study, the. As shown in Table 1 below, participants in this study sample were young, with a mean age of 33 years among the patients and 35 years among the controls. Cases were more likely to be married compared to controls (35%vs 55%, p<0.001) Cases were more likely to be unemployed compared to controls (48% vs. 23%, p<0.001). Cases were less likely to have attained tertiary education (26%vs 56% P<0.001).

Compared to controls, patients were more likely to have smoked in their lifetimes (13.8% patients vs. 7% controls, p=0.006) or to be current smokers (9.8% vs. 3.3%, p=0.001). Almost all patients (97%) consumed inadequate fruits and vegetables; most (78%) had inadequate physical activity and almost half (48%) had significant sedentary behaviour. Of note, statistically significant differences in physical activity and dietary habits were not found between patients and controls, Table 2.

10-year estimated risk of developing CVDs

In this study, the FRS among patients with psychosis was 3.16, which was comparable to that in the control group (2.93). Table 3. Most patients (94.6%) had a low-risk score (<10), 4.4% had an intermediate risk and 1.0% had high risk for CVD.

Discussion

This study describes the modifiable CVD risk factors and estimated 10-year risk score among patients managed for psychotic disorders in Kenya and how this compares to the general population. To the best of our knowledge, this is the first study to explore this in this setting. A key finding was that patients with psychosis (compared to controls) were more likely to have smoked in their lifetimes, or to be current smokers. Most patients consumed inadequate fruits and vegetables, and had low levels of physical activity, almost half of patients reported sedentary behaviour but these findings were comparable to the control group. Of note, the estimated 10-year cardiovascular

Table 1 Social demographic characteristics of participants

Variable	Total	Case	Control	P-value
Age in years	34.81 (10.33)	33 (26,40)	35 (26,5,41)	0.383 ³
Sex				0.238 ¹
Male	265 (44.4)	139 (46.8)	126 (42.0)	
Female	332 (55.6)	158 (53.2)	174 (58.0)	
Marital status				< 0.001 ¹
Married	269 (45.1)	103 (34.7)	166 (55.3)	
Never married	239 (40)	139 (46.8)	100 (33.3)	
Widow/separated/divorced	89 (14.9)	55 (18.5)	34 (11.3)	
Highest level of Education				< 0.001 ¹
None	35 (5.9)	23 (7.7)	12 (4)	
Primary	147 (24.6)	106 (35.7)	41 (13.7)	
Secondary	172 (28.8)	92 (31)	80 (26.7)	
Tertiary	243 (40.7)	76 (25.6)	167 (55.7)	
Occupation				< 0.001 ¹
Unemployed	217 (36.3)	143 (48.1)	74 (24.7)	
Formal	187 (31.3)	43 (14.5)	144 (48)	
Self	193 (32.3)	11(17.4)	82 (27.3)	

Table 2 Lifestyle CVD risk factors

Variable	Total Frequency (%)	Cases N (297) Frequency (%)	Controls N (300) Frequency (%)	p-value
Current smoker				0.001 ¹
No	558 (93.5)	268 (90.2)	290 (96.7)	
Yes	39 (6.5)	29 (9.8)	10 (3.3)	
Ever smoked				0.006 ¹
No	535 (89.6)	256 (86.2)	279 (93)	
Yes	62 (10.4)	41 (13.8)	21 (7)	
Harmful alcohol				0.648 ²
No	579 (97.0)	289 (97.3)	290 (96.7)	
Yes	18 (3.0)	8 (2.7)	10 (3.3)	
Poor diet				0.352 ²
No	11 (1.8)	7 (2.4)	4 (1.3)	
Yes	586 (98.2)	290 (97.6)	296 (98.7)	
Inadequate exercise				0.084 ¹
No	114 (19.1)	65 (21.9)	49 (16.3)	
Yes	483 (80.9)	232 (78.1)	251 (83.7)	
Time spent sitting				0.906 ¹
< 3 h in a day	311 (52.1)	154 (51.9)	157 (52.3)	
> 3 h in a day	286 (47.9)	143 (48.1)	143 (47.7)	

¹Chi square test²Fishers' exact test

Table 3 A comparison of framingham risk score between patients and controls

Framingham Score	Total Freq (%)	Control Freq (%)	Case Freq (%)	p-value
Low risk	563 (94.3)	282 (94.0)	281 (94.6)	1.000
Intermediate	27 (4.5)	14 (4.7)	13 (4.4)	
High Risk	7 (1.2)	4 (1.3)	3 (1.0)	

In a multiple linear regression model adjusted for key covariates, the FRS among patients was significantly associated with female sex ($p=0.007$), age ($p<0.001$), current tobacco smoking ($p<0.001$), and metabolic syndrome ($p<0.001$). Table 4

risk among patients (and controls) was low. In the patient group, this risk was found to be associated with female sex, current tobacco smoking and presence of metabolic syndrome.

In this study, 13.8% of patients reported cigarette smoking. This finding is comparable to the prevalence of smoking (13.5%) in the general population in Kenya [37]. However, a recent study of patients with schizophrenia in Nigeria reported a lifetime prevalence of 25% [38]. Moreover, a review and meta-analysis (including 61 studies, 72 samples and a total of 14,555 tobacco users and 273,162 non-users) reported a smoking prevalence of 57%, amongst patients with first episode psychosis [39]. The lower prevalence found in the current study may be attributable to underreporting of smoking, potentially due to perceived and/or internalized stigma associated with substance use. The higher prevalence of smoking among patients versus controls in the current study is also in line with well-established evidence. For example,

Table 4 Factors associated with higher 10-year FRS among patients

Variable	Coefficient	p-value	95% Confidence interval
Female	0.888	0.007	1.528; -0.248
Age	0.239	< 0.001	0.2090 0.268
Employment: formal vs. none	0.476	0.307	-1.413 0.460
Education: secondary vs. none	0.184	0.770	-1.433 1.064
Obesity	0.466	0.176	-0.210 1.142
Current tobacco use	3.817	< 0.001	2.717 4.917
Harmful alcohol use	0.884	0.369	-1.051 2.819
Metabolic syndrome	3.092	< 0.001	2.319 3.865
Olanzapine dose			
< 10 mg vs. none ¹	0.438	0.337	0.458 1.335
> 10 mg vs. none	0.367	0.478	0.651 1.385

¹Olanzapine was used because 85% of the patients were on olanzapine being a donated drug in this setting

patients with psychotic disorders have been reported to be 4 to 6 times more likely to smoke, compared to those without psychosis [40].

In the current study, only 2.7% of the patients with psychosis reported harmful alcohol use - this did not differ significantly from the control group (3.3%). This prevalence is notably lower than expected, given that a recent community-based study in the same region of Western Kenya found that the prevalence of harmful alcohol use was 12% [41]. Further, one meta-analysis of 123 studies (totalling 165,811 participants) reported that 24% of patients with schizophrenia had a co-morbid alcohol use disorder [42]. This lower prevalence of harmful alcohol use in our study may reflect social desirability bias due to attitudes related to alcohol use in this setting [43, 44], thus suggesting a need for more objective measures of alcohol use such as blood or urine tests in future work.

In this study, almost all patients with psychosis as well as controls reported eating less than one serving of fruit per week, and fewer than three servings of vegetables per week. This trend of sub-optimal intake of fruits and vegetables was also reported in a Kenyan cross sectional study that only 12.4% of participants had two or more servings of fruit a day, only 7.4% had three or more servings of vegetables a day and 94.0% had less than five servings of fruits and vegetables a day [45]. The suboptimal intake of fruits and vegetables has been attributed to symptoms of the illness (particularly negative symptoms and cognitive impairment); as well as to low financial abilities, which would limit purchasing power for healthy meals [46, 47].

This study reported inadequate exercise among a vast majority of patients and controls, as quantified by number of physical activities per week. Though no study has

documented physical activity among patients with psychosis in Kenya, the 2015 WHO Steps Survey, reported that up to 80% of the population in Kenya do not engage in adequate physical activity, which could be assumed to include those with psychosis [48]. Similarly, a recent systematic review (including a total of 2,033 patients with psychosis) reported that patients with psychosis may spend up to 9 h of their wakefulness in a sedentary state; and at least 2 h more is spent in a sedentary state, compared to the general population [49]. Another systematic review of 25 studies reported an association between low physical activity in patients with psychosis and negative symptoms (e.g. anhedonia); side-effects of antipsychotic medication, lack of knowledge of CVD risk factors, lack of belief in the health benefits of physical activity and lower self-efficacy; and social isolation [50]. Similarly, a review of 35 studies (totalling 3,453 individuals with schizophrenia) found an association between low physical activity levels, and comorbid depressive symptoms [51].

In the current study, almost half of the patients reported spending more than three hours per day sitting, which did not differ significantly from the controls. This is in contrast to findings of a global meta-analysis that patients with mental illness have more sedentary behaviour, when compared to the general population [52]. Further, a systematic review and meta-analysis (including 2,033 participants with psychosis) reported that patients spent an average of 11 h per day in sedentary behaviour – about 2.8 h more than the general population [49]. Contributing factors to low physical activity in this patient population may include impaired cognition, depression, mobility difficulties and self-care challenges.

The estimated 10-year risk of developing cardiovascular-related events among the patients in this study was low. This finding is in line with recent work in Brazil among patients with psychosis which reported that only 1.2% of the study population had severe FRSs [53]. This is in contrast to the findings of the Clinical Trials of Antipsychotic Treatment Effectiveness (CATIE) schizophrenia study which reported significantly elevated FRSs among patients with schizophrenia compared to controls – both for males (9.4% in patients vs. 7.0% in controls) and females (6.3% vs. 4.2%) [54]. Similarly, a study in Lebanon of 329 patients with schizophrenia reported that 31.6% of the participants had intermediate risk of developing CVD, while 7.6% had high risk [55]. Further, a study in China (of 83 patients with schizophrenia and 243 controls) also reported that patients had a higher mean 10-year CVD risk (4.6%), compared to controls (3.1%) [56]. These inconsistencies may – in part – reflect the young age of participants in the current study [57], as well as the overall low CVD risk in the study setting. For example, one cross-sectional survey of slum dwellers in Nairobi found that the CVD risk score was low with

only 1.7% of the study sample having a high risk score [58]. In this study, FRSs were significantly associated with female sex and smoking. These findings are consistent with those of a study in China of 83 patients with schizophrenia and 243 controls, which reported that smoking and Metabolic disorder were the leading contributors of increased CVD risk [56].

The current study provides novel and clinically relevant preliminary data of lifestyle CVD risk profile among patients with psychosis in Eldoret, Kenya. Nonetheless, several methodological limitations should be borne in mind when interpreting these study findings. First, an observational study design was undertaken, thus potential causal relationships between psychosis and lifestyle CVD risk could not be ascertained. Second, most data on tobacco use, alcohol consumption, exercise and diet were self-reported, which is likely to have introduced reporting bias. Third, the use of absolute scores to describe CVD risk is limited. For example, the relatively low FRS in our patient group may have been skewed by the young age of the study participants. In addition, FRSs represent average values without considering individual variability in risk. In future, studies assessing the FRS in older participants in our setting; comparing utility of different risk scores would be considered. Lastly, we acknowledge the limitation associated with the enrolment process for cases and control which limits the understanding this may impact on the results.

Despite these limitations, this study highlights the burden of lifestyle risk factors among patients with psychotic disorders in Western Kenya. To address this burden, strategies that are achievable in resource-limited settings are needed. For example, incorporating lifestyle modification activities (with attention to diet and exercise) into routine care would be beneficial in promoting both the mental well-being and cardiovascular health of patients with psychosis [59]. Such activities may include targeted behavioural weight loss [60, 61], in which physicians collaboratively identify physical activity goals for specific patients, reinforce efforts to reach the targets, and continuously address barriers to physical activity [62]. Clinicians should also routinely discuss and encourage healthy and culturally appropriate diets (such as fresh fruit and vegetables and meals made at home); and discourage unhealthy foods (such as fast foods and hotel foods) [63]. Early involvement of nutritionists for individual and group support (where possible) is also key in promoting healthy diets [64]. In addition, strategies should be employed to mitigate potential poor adherence to these lifestyle changes; and to promote long-term reduction in CVD risk [65]. Such strategies may include psychoeducation group sessions and use of incentives [66].

Prevention or cessation of alcohol consumption and cigarette smoking should also be incorporated into the

care of patients with psychosis [67]. Although smoking cessation is an efficacious and cost-effective method of improving cardiovascular health [68], cessation therapies are not widely implemented. This may, in part, be due to the perception that smoking is a “lifestyle choice”; and that relapse is common [69]. Medication to assist smoking cessation, such as bupropion and nicotine replacement therapies - as well as group and individual psychotherapies - should also be routinely incorporated into care, where feasible [70]. Further work is recommended to establish the causal and temporal relationships between psychosis and CVD risk factors and how best to promote physical health among patients with psychosis.

Abbreviations

CVD	Cardiovascular Disorders
FRS	Framingham risk score
MTRH	Moi Teaching and Referral Hospital
NeuroGAP	Neuropsychiatric Genetics of African Populations
WHO	World Health Organization

Acknowledgements

I am grateful to Research Assistants Stella, Eunice, Freddie, Ndenga and Julius for assisting with data collection and study logistics.

I am grateful to my employer, Moi teaching and referral hospital headed by Dr Aruasa for supporting my research activities.

Authors' contributions

EK conceptualised and drafted the manuscript. DJS, LA NK AM reviewed and edited the manuscript. All Authors reviewed and approved the manuscript for final submission.

Funding

The PHD studies from which this paper was developed was funded by the Neuropsychiatric Genetics of African Populations (NeuroGAP) initiative, a multi-site project supported by the Stanley Centre for Psychiatry Research at the Broad Institute, USA. The tuition fee was supported by NeuroGAP and the Department of Psychiatry and Mental Health, University of Cape Town. The research fees were supported by NeuroGAP and the Department of Psychiatry, Moi University. The funders had no role in the design of the study, collection, analysis, interpretation of data or in writing the manuscript.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Written Informed consent was obtained from all participants. Ethics review and approval was obtained from the MTRH/Moi University School of Medicine Institutional Research and Ethics Committee (IREC/2017/90) and from the Human Research Ethics Committee of the Faculty of Health Sciences, University of Cape Town (FHS HREC/286/2017).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Psychiatry, Moi Teaching and Referral Hospital, Eldoret, Kenya

²Department of Psychiatry and Mental Health & Neuroscience Institute, South African Medical Research Council (SAMRC) Unit on Risk and Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa

³Department of Mathematics, Physics and Computing, School of Science and Aerospace Studies, Moi University, Eldoret, Eldoret, Kenya

⁴Brain and Mind Institute, Department of Medicine, The Aga Khan University, East Africa, Nairobi, Kenya

⁵South Africa Medical Research (SAMRC) Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa

Received: 10 November 2022 / Accepted: 27 November 2023

Published online: 05 December 2023

References

- Melo APS, Dippenaar IN, Johnson SC, Weaver ND, Acurcio F, de Malta A. All-cause and cause-specific mortality among people with severe mental illness in Brazil's public health system, 2000–15: a retrospective study. *Lancet Psychiatry*. 2022;9(10):771–81.
- Cardiovascular diseases. [cited 2022 Oct 17]. Available from: <https://www.who.int/health-topics/cardiovascular-diseases>.
- Nielsen RE, Banner J, Jensen SE. Cardiovascular Disease in patients with severe mental illness. *Nat Rev Cardiol*. 2021;18(2):136–45.
- Hajar R. Risk factors for coronary artery Disease: historical perspectives. *Heart Views off J Gulf Heart Assoc*. 2017;18(3):109–14.
- Institute for Health Metrics and Evaluation. 2021 [cited 2022 Oct 17]. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Available from: <https://www.healthdata.org/research-article/spatial-temporal-and-demographic-patterns-prevalence-smoking-tobacco-use-and-0>.
- Gallucci G, Tartarone A, Lerosé R, Lalinga AV, Capobianco AM. Cardiovascular risk of Smoking and benefits of smoking cessation. *J Thorac Dis*. 2020;12(7):3866.
- Quigley H, MacCabe JH. The relationship between nicotine and psychosis. *Ther Adv Psychopharmacol*. 2019;9:2045125319859969.
- Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. *The Lancet*. 2018;392(10152):1015–35.
- Piano MR. Alcohol's effects on the Cardiovascular System. *Alcohol Res Curr Rev*. 2017;38(2):219–41.
- Krystal JH, D'Souza DC, Gallinat Jü, Driesen N, Abi-Dargham A, Petrakis I, et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. *Neurotox Res*. 2006;10(3):235–52.
- Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. *BMJ*. 2016 [cited 2020 Jan 24];354. Available from: <https://www-bmj-com.ezproxy.uct.ac.za/content/354/bmj.i3857>.
- Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic Diseases. *Compr Physiol*. 2012;2(2):1143.
- Ding D, Lawson KD, Kolbe-Alexander TL, Finkelstein EA, Katzmarzyk PT, van Mechelen W, et al. The economic burden of Physical Inactivity: a global analysis of major non-communicable Diseases. *The Lancet*. 2016;388(10051):1311–24.
- Myers J. Exercise and Cardiovascular Health. *Circulation*. 2003 [cited 2019 Oct 12];107(1). Available from: <https://www.ahajournals.org/doi/https://doi.org/10.1161/01.CIR.0000048890.59383.8D>.
- Wahid Ahad M, Nishma N, Melanie K, Paul F, Charlie W, Premila, et al. Quantifying the Association between Physical Activity and Cardiovascular Disease and Diabetes: a systematic review and Meta-analysis. *J Am Heart Assoc*. 2016;5(9):e002495.
- Prasad D, Das B. Physical Inactivity: a cardiovascular risk factor. *Indian J Med Sci*. 2009;63(1):33.

17. Ekelund U, Steene-Johannessen J, Brown WJ, Fagerland MW, Owen N, Powell KE, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. *The Lancet*. 2016;388(10051):1302–10.
18. Krishnaswamy K, Gayathri R. Nature's bountiful gift to humankind: vegetables & fruits & their role in Cardiovascular Disease & Diabetes. *Indian J Med Res*. 2018;148(5):569–95.
19. Locke A, Schneiderhan J, Zick SM. Diets for Health: goals and guidelines. *Am Fam Physician*. 2018;97(11):721–8.
20. Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, et al. Fruit and vegetable intake and the risk of Cardiovascular Disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. *Int J Epidemiol*. 2017;46(3):1029–56.
21. Dipasquale S, Pariente CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. *J Psychiatr Res*. 2013;47(2):197–207.
22. Teasdale SB, Ward PB, Samaras K, Firth J, Stubbs B, Tripodi E, et al. Dietary intake of people with severe mental illness: systematic review and meta-analysis. *Br J Psychiatry*. 2019;214(5):251–9.
23. Foguet-Boreu Q, Fernandez San Martin MI, Flores Mateo G, Zabaleta del Olmo E, Ayerbe García-Morzon L, Perez-Piñar López M, et al. Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis. *BMC Psychiatry*. 2016;16:141.
24. D'Agostino Ralph B, Vasani Ramachandran S, Pencina Michael J, Wolf PA, Mark C, Massaro Joseph M, et al. General Cardiovascular Risk Profile for Use in Primary Care. *Circulation*. 2008;117(6):743–53.
25. Jin H, Folsom D, Sasaki A, Mudaliar S, Henry R, Torres M, et al. Increased Framingham 10-year risk of Coronary Heart Disease in middle aged and older patients with psychotic symptoms. *Schizophr Res*. 2011;125(2–3):295–9.
26. Stevenson A, Akena D, Stroud RE, Atwoli L, Campbell MM, Chibnik LB et al. Neuropsychiatric Genetics of African Populations-Psychosis (NeuroGAP-Psychosis): a case-control study protocol and GWAS in Ethiopia, Kenya, South Africa and Uganda. *BMJ Open*. 2019 [cited 2021 Apr 28];9(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377543/>.
27. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol*. 1996;49(12):1373–9.
28. Kaduka LU, Kombe Y, Kenya E, Kuria E, Bore JK, Bukania ZN, et al. Prevalence of metabolic syndrome among an Urban Population in Kenya. *Diabetes Care*. 2012;35(4):887–93.
29. Saloojee S, Burns JK, Motala AA. Metabolic Syndrome in South African Patients with Severe Mental Illness: Prevalence and Associated Risk Factors. *PLoS ONE*. 2016 [cited 2016 Jun 19];11(2). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755575/>.
30. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. *World Psychiatry*. 2013;12(2):92–8.
31. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, et al. A new brief instrument for assessing decisional capacity for clinical research. *Arch Gen Psychiatry*. 2007;64(8):966–74.
32. Lain KY, Catalano, Patrick. Metabolic changes in pregnancy | Ovid. *Clin Obstet Gynecol*. 2007;57(4):938–48.
33. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31(7):1208–17.
34. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for Problem drinking. *Arch Intern Med*. 1998;158(16):1789–95.
35. Riley L, Guthold R, Cowan M, Savin S, Bhatti L, Armstrong T, et al. The World Health Organization STEPwise Approach to Noncommunicable Disease risk-factor surveillance: methods, challenges, and opportunities. *Am J Public Health*. 2016;106(1):74–8.
36. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. *Circulation*. 2004;109(3):433–8.
37. Ngaruiya C, Abubakar H, Kiptui D, Kendagor A, Ntakuka MW, Nyakundi P, et al. Tobacco use and its determinants in the 2015 Kenya WHO STEPS survey. *BMC Public Health*. 2018;18(3):1223.
38. Aguocha CM, Aguocha JK, Igwe M, Uwakwe RU, Onyeama GM. Prevalence and correlates of cigarette Smoking among patients with schizophrenia in southeast Nigeria. *Acta Psychiatr Scand*. 2015;131(3):206–12.
39. Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does Tobacco use cause psychosis? Systematic review and meta-analysis. *Lancet Psychiatry*. 2015;2(8):718–25.
40. Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, Knowles JA, et al. Comorbidity of severe psychotic disorders with measures of substance use. *JAMA Psychiatry*. 2014;71(3):248–54.
41. Kwobah E, Epstein S, Mwangi A, Litzelman D, Atwoli L. PREVALENCE of psychiatric morbidity in a community sample in Western Kenya. *BMC Psychiatry*. 2017 [cited 2019 Jun 29];17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242046/>.
42. Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. *Drug Alcohol Depend*. 2018;191:234–58.
43. Boniface S, Kneale J, Shelton N. Drinking pattern is more strongly associated with under-reporting of alcohol consumption than socio-demographic factors: evidence from a mixed-methods study. *BMC Public Health*. 2014 [cited 2019 Jul 7];14. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320509/>.
44. Northcote J, Livingston M. Accuracy of self-reported drinking: Observational Verification of 'Last occasion' drink estimates of young adults. *Alcohol Alcohol*. 2011;46(6):709–13.
45. Pengpid S, Peltzer K. The prevalence and social determinants of fruit and vegetable consumption among adults in Kenya: a cross-sectional national population-based survey, 2015. *Pan Afr Med J*. 2018;31:137.
46. Hahn LA, Galletly CA, Foley DL, Mackinnon A, Watts GF, Castle DJ, et al. Inadequate fruit and vegetable intake in people with psychosis. *Aust N Z J Psychiatry*. 2014;48(11):1025–35.
47. Samele C, Patel M, Boydell J, Leese M, Wessely S, Murray R. Physical Illness and lifestyle risk factors in people with their first presentation of psychosis. *Soc Psychiatry Psychiatr Epidemiol*. 2007;42(2):117–24.
48. Wekesah FM, Nyanjau L, Kibachio J, Mutua MK, Mohamed SF, Grobbee DE et al. Individual and household level factors associated with presence of multiple non-communicable disease risk factors in Kenyan adults. *BMC Public Health*. 2018 [cited 2019 Oct 21];18(Suppl 3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219015/>.
49. Stubbs B, Williams J, Gaughran F, Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. *Schizophr Res*. 2016;171(1):103–9.
50. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, Hert MD. A systematic review of correlates of physical activity in patients with schizophrenia. *Acta Psychiatr Scand*. 2012;125(5):352–62.
51. Stubbs B, Firth J, Berry A, Schuch FB, Rosenbaum S, Gaughran F, et al. How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression. *Schizophr Res*. 2016;176(2):431–40.
52. Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. *World Psychiatry*. 2017;16(3):308–15.
53. Benseñor IM, Brunoni AR, Pílan LA, Goulart AC, Busatto GF, Lotufo PA, et al. Cardiovascular risk factors in patients with first-episode psychosis in São Paulo, Brazil. *Gen Hosp Psychiatry*. 2012;34(3):268–75.
54. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res*. 2005;80(1):45–53.
55. Haddad C, Hallit S, Salameh P, Bou-Assi T, Zoghbi M. Coronary Heart Disease risk in patients with schizophrenia: a Lebanese cross-sectional study. *J Comorbidity*. 2017;7(1):79–88.
56. Tay YH, Nurjono M, Lee J. Increased Framingham 10-year CVD risk in Chinese patients with schizophrenia. *Schizophr Res*. 2013;147(1):187–92.
57. Jousilahti Pekka V, Erkki T, Jaakko PP. Sex, Age, Cardiovascular Risk factors, and Coronary Heart Disease. *Circulation*. 1999;99(9):1165–72.
58. Vusirikala A, Wekesah F, Kyobutungi C, Oyebo O. Assessment of cardiovascular risk in a slum population in Kenya: use of World Health Organisation/ International Society of Hypertension (WHO/ISH) risk prediction charts - secondary analyses of a household survey. *BMJ Open*. 2019;9(9):e029304.
59. Bonfili E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. *BMC Psychiatry*. 2012;12(1):78.
60. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CAM, et al. A behavioral weight-loss intervention in persons with serious mental illness. *N Engl J Med*. 2013;368(17):1594–602.
61. Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Naslund JA, Wolfe R, et al. Pragmatic Replication Trial of Health Promotion Coaching for Obesity in

- Serious Mental Illness and maintenance of outcomes. *Am J Psychiatry*. 2015;172(4):344–52.
62. Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating Physical Activity into Mental Health Services for persons with Serious Mental Illness. *Psychiatr Serv*. 2005;56(3):324–31.
63. Pérez-Martínez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. *Nutr Rev*. 2017;75(5):307–26.
64. Teasdale SB, Ward PB, Rosenbaum S, Samaras K, Stubbs B. Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness. *Br J Psychiatry*. 2017;210(2):110–8.
65. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Systematic Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 [cited 2020 Feb 4]. (U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK476368/>.
66. Andrade C. Cardiometabolic risks in Schizophrenia and directions for intervention, 2: nonpharmacological interventions. *J Clin Psychiatry*. 2016;77(8):964–7.
67. Compton MT, Daumit GL, Druss BG. Cigarette Smoking and Overweight/Obesity among individuals with Serious Mental illnesses: a preventive perspective. *Harv Rev Psychiatry*. 2006;14(4):212–22.
68. Lee H, Son YJ. Influence of Smoking Status on Risk of Incident Heart Failure: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Int J Environ Res Public Health*. 2019 [cited 2019 Oct 20];16(15). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696428/>.
69. Erhardt L. Cigarette Smoking: an undertreated risk factor for Cardiovascular Disease. *Atherosclerosis*. 2009;205(1):23–32.
70. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. *Cochrane Database Syst Rev*. 2013 [cited 2018 Oct 27];(2). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007253.pub3/abstract>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com